Skip to content

Depreciation at other companies

Revvity logo
RevvityRVTY
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-4.6%
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%
Debt / equity+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's depreciation?
Charles River Laboratories (CRL) reported depreciation of $41.3M in Q1 2026.
How has Charles River Laboratories's depreciation changed year-over-year?
Charles River Laboratories's depreciation decreased by 4.8% year-over-year, from $43.4M to $41.3M.
What is the long-term trend for Charles River Laboratories's depreciation?
Over 2 years (2023 to 2025), Charles River Laboratories's depreciation has grown at a 0.3% compound annual growth rate (CAGR), from $176.7M to $177.6M.